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Abstract 
 
Hypoxic environments in the core of tumors can give rise to resistance against anti-cancer 
therapeutics. Oxygen producing biomaterials may be able to improve chemotherapeutic 
efficiency by locally disrupting the hypoxic environment. We hypothesized that gellan gum 
hydrogels could be loaded with both a solid peroxide and the chemotherapeutic drug 
doxorubicin, to release both oxygen and doxorubicin simultaneously. We show that calcium 
peroxide physically crosslinks gellan gum into a hydrogel which, when loaded with catalase, 
raises the dissolved oxygen content of media for up to 64 hours. Additionally doxorubicin 
could be loaded into the hydrogel in situ, allowing release in well-defined quantities.     
 
Main Text 
 
Gellan gum is an FDA approved food additive that has more recently been analyzed for 
hydrogel applications in tissue engineering and regenerative medicine. These applications 
include bone regeneration,1 cartilage repair,2 intervertebral disc regeneration,3-4 neuronal cell 
culture5-7 and spinal cord injury therapies.8 The divalent calcium cation derived from calcium 
chloride is typically used to physically crosslink gellan gum into a hydrogel structure.9 From 
this starting point, we wanted to assess whether calcium peroxide could be used instead of 
calcium chloride, to from physically crosslinked hydrogels capable of releasing oxygen to 
cells in culture without causing toxicity.  
 
Oxygen producing biomaterials are a relatively recently developed phenomenon, which have 
largely focused on the incorporation of solid peroxides for applications in tissue 
engineering10-11 or cell transplantation.12 The solid peroxide relies on the presence of water to 
produce hydrogen peroxide as an intermediate followed by water and oxygen.12 Other oxygen 
producing materials have encapsulated liquid hydrogen peroxide13, but both methods rely on a 
catalyst (commonly catalase) to ensure complete conversion to the final oxygen product 
without peroxide induced toxicity. For biological applications solid peroxides must be 
encapsulated in a surrounding matrix because a basic by-product is formed during the reaction 
(Ca(OH)2 in the case of calcium peroxide). Encapsulating materials have consisted of 
polydimethylsiloxane (PDMS),12 methacrylated gelatin14 or poly(d,l-lactide–co–glycolide).10-
11
 These materials effectively hold the solid peroxide and byproduct in place and can limit 
water diffusion to the peroxide to try and slow the oxygen release rate.  
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To date, the natural polysaccharide gellan gum has not been investigated for encapsulating a 
solid peroxide for oxygen delivery. Additionally, oxygen producing biomaterials for use in 
anticancer applications has been largely overlooked. Since hypoxia plays an important role in 
cancer drug resistance,15-16 oxygen producing materials may potentially be effective at 
disrupting the hypoxic environment of a tumor core. We were therefore interested to see if 
gellan gum hydrogels could also be used to simultaneously deliver oxygen and the 
chemotherapeutic drug doxorubicin.  
 
The aim of this study was to create a dual delivery system that could either deliver oxygen or 
peroxide in conjunction with a model anti-cancer drug, doxorubicin. We hypothesized that 
calcium peroxide could be used to physically crosslink gellan gum into a hydrogel instead of 
the commonly used calcium chloride. Additionally, we hypothesized that doxorubicin could 
be incorporated during the gelation process and be released in defined quantities. The specific 
objectives of this study were to compare gellan gum hydrogels crosslinked with calcium 
chloride (termed control) and calcium peroxide (termed oxyGG) in terms of rheological 
properties and oxygen production. The cytotoxicity of oxyGG with and without catalase and 
with and without prior loading of doxorubicin was also performed.   
 
Four oxygen producing gellan gum hydrogels (oxyGG)(always 1% w/v) were produced using 
varying degrees of calcium peroxide content (w/v) from 0.1% (oxyGG 0.1%), 0.5% (oxyGG 
0.5%), 1% (oxyGG 1%) and 2% (oxyGG 2%). Since divalent cations are required for the 
physical gelation of gellan gum, control hydrogels were produced using 0.5% w/v calcium 
chloride (CaCl2). The hydrogels consisted of gellan gum (Gelzan™ CM, Sigma) dissolved in 
deionized water at 90°C. After cooling to 60°C, HEPES buffer and HCl were added to 
maintain a pH of 7.4 upon the addition of calcium peroxide. Catalase (10 units per gel) was 
then added and lastly the calcium peroxide was added immediately prior to hydrogel casting. 
The reaction solution formed a hydrogel upon cooling to room temperature in a cylindrical 
mold of 8 mm in diameter and 1 mm deep (detailed methods are available in the supporting 
information). The schematic diagram in figure 1 shows a depiction of the five component 
system which relies on the influx of aqueous solution (in this case phosphate buffered saline 
(PBS) or cell culture media) to react with the calcium peroxide to produce hydrogen peroxide 
and in turn oxygen. The presence of catalase within the hydrogel ensures the hydrogen 
peroxide is converted to molecular oxygen and the water byproduct, and is essential of 
maintaining high cellular viability.  
 
The hydrogel is formed via Ca2+ ions physically crosslinking the gellan gum network. The 
stiffness of the hydrogel networks (G’ in figure 1c and supporting information figure S1) 
was measured by rheology and it was shown the that all hydrogels formed from CaO2 were 
much less stiff than those formed from 0.5% w/v CaCl2. The lower solubility of CaO2 (only 
1.72g/L at 20oC) results in less free Ca2+ ions for crosslinking the gel. Simply cooling gellan 
gum back to room temperature without the addition of either CaO2 or CaCl2 did not result in 
hydrogel formation. Upon analysis of the structure of the dehydrated gels by scanning 
electron microscopy (SEM), a distinct difference could be observed between those gels that 
contained calcium peroxide and those containing CaCl2 (figure 1b). The difference in surface 
morphology was particularly apparent for the highest amount of calcium peroxide tested (2% 
w/v), which showed a highly porous structure, presumably due to the large amount of gaseous 
oxygen produced throughout the structure. This change in structure could account for the 
reduced stiffness of the oxyGG 0.5% hydrogels compared to the hydrogels formed with 0.5% 
w/v CaCl2. 
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Figure 1. Oxygen producing gellan gum hydrogels have variable stiffness. A schematic 
depiction (a) of the multi-component hydrogel, containing gellan gum, calcium peroxide 
(CaO2), and catalase which is neutralized and buffered by hydrochloric acid and HEPES 
buffer respectively. SEM images (b) of control hydrogels where calcium chloride is used 
instead of calcium peroxide (CaCl2 (0.5% wt/vol)), in comparison with the oxygen producing 
CaO2 0.5% w/v, and 1% w/v hydrogels showing the change in morphology due to oxygen 
production. Rheological analysis (c) of the different gel compositions showing that control 
hydrogels with CaCl2 (0.5% w/v) are stiffer than all other formulations (n=5, error bars 
removed for clarity). See supporting information for further SEM and rheological analysis.  
 
Oxygen production was analyzed for hydrogels composed of 0.1%, 0.5% and 1% calcium 
peroxide using a PreSens non-invasive oxygen sensor. Catalase is used for the decomposition 
of H2O2 via the Fe2+/Fe3+ within the catalase, to avoid unwanted side reactions and cellular 
damage.17 Catalase was incorporated directly into the gellan gum hydrogel during gelation 
and was not added to the surrounding medium. Oxygen production was analyzed in open 
cuvettes in both normoxic and hypoxic conditions, by first allowing PBS to equilibrate before 
adding the oxyGG hydrogel disks into the cuvette. The oxygen release profile was clearly 
dependent on the amount of calcium peroxide within the hydrogel, and was similar for both 
conditions, but with greater values reached in normoxia (figure 2). In normoxic conditions the 
oxyGG (0.5%) caused a 220% rise in dissolved oxygen content, therefore more than double 
that of PBS left in atmospheric conditions. The oxyGG (1%) hydrogel caused an even greater 
increase in oxygenation (485% rise). The oxyGG (0.5%) and oxyGG (1%) hydrogels resulted 
in oxygen levels that stayed elevated above the PBS control for between 24 and 64 hours, and 
both were longer above the PBS control baseline in hypoxic conditions. The pH of the PBS 
was analyzed over the entire release period in order to check that the hydrogels buffered with 
HEPES did not cause a rise in pH over time. Unlike pure calcium peroxide that caused a rise 
in pH to 10.7 over 72 hours, oxyGG 0.1%, 0.5% and 1% cause no increase in pH over this 
time (see supporting information figure S2). These data show that oxyGG hydrogels can 
deliver large amounts of oxygen into solution for two days without causing a rise in pH. The 
level of oxygen in tumors is highly variable but to give some context for the oxygen 
production herein, primary brain tumors have an oxygen partial pressure of 13 mmHg (≈ 
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0.718 mg/L O2)(normal brain is estimated at 35 mmHg (≈ 1.933 mg/L O2).18 It is clear that 
the rise in dissolved oxygen to 15mg/mL by the oyxGG (0.5%) formulation under extreme 
hypoxic conditions represents a large oxygen production, and so was used for further studies 
for cytotoxicity analysis and oxygen delivery in vitro.    
 
 
 
Figure 2. Tunable release of either oxygen or doxorubicin can be achieved from gellan gum 
hydrogels. Oxygen release profiles of oxygen producing gellan gum hydrogels (oxyGG) with 
varying percentage (w/v) of calcium peroxide (indicated in brackets), showing that the oxygen 
release profile can be tuned by varying the calcium peroxide content. The oxygen release in 
normoxic conditions (a) shows higher peak oxygen values for all groups than when the 
oxyGG hydrogels are analyzed in severe hypoxic conditions (0.1% oxygen) (b). The control 
group is a hydrogel formed with calcium chloride for both analyses. Doxorubicin is released 
from the hydrogels over a period of ~ 2 hours, as shown in a representative release curve (c) 
and the final concentration closely corresponds to the initial amount loaded in the hydrogels 
(d) (n=3, error bars represent +/- standard deviation).For oxygen release curves for oxyGG 
hydrogels without catalase please see supporting information figure S8 and S9. 
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Aside from the predominant mechanism of doxorubicin action (intercalating with DNA base 
pairs causing DNA damage (including mitochondrial DNA)),19 doxorubicin can also bind cell 
membrane proteins directly causing the production of highly reactive species of hydroxyl 
radicals.20 Hypoxia has been shown to reduce the cytotoxic action of doxorubicin via HIF 
related pathways, the induction of MAX dimerization protein 1 (Mad1)21 or the induction of 
the multidrug resistance-associated protein 1 gene (MRP1).22 It was therefore desired to 
analyze whether doxorubicin could be loaded to the oxyGG hydrogels during gelation and 
what amount of it would be released into the surrounding media. Hydrogels were formed with 
different amounts of doxorubicin varying from 0.635 µg to 5 µg and placed into 1 mL of 
phosphate buffered saline (PBS) and kept at 37oC in a sealed cuvette. Cumulative doxorubicin 
release was measured by UV absorbance at 490 nm for 1000 minutes. An example set of 
release curves are shown in figure 2c. The majority of the doxorubicin is released from the 
hydrogels in the first two hours of incubation, probably due to the inert and uncharged 
polysaccharide structure of gellan gum. The final concentrations from three such experiments 
were averaged and plotted in figure 2d which shows that the amount of doxorubicin released 
corresponds almost exactly to the amount loaded during gelation.   
 
With the capacity for dual delivery of both oxygen and doxorubicin we wanted to see if the 
high amount of oxygen released from the oxyGG hydrogels could improve the action of 
doxorubicin against C6 cells in vitro. C6 cells are a rat glioblastoma cell line which have 
previously been used to study the induction of hydroxyl radical (HO•) due to treatment with 
doxorubicin.23 However, first we analyzed whether the oxGG hydrogels would be inherently 
toxic due to the high level of oxygen production. For this study, primary astrocytes extracted 
from the newborn rat 24 were used as a test platform to represent a predominant cell type of 
the brain. Toxicity analysis was performed using a combination of the PrestoBlue assay 
(which measures cell metabolic activity), the Quant-iT PicoGreen assay (which measures total 
DNA content) and light microscopy. Interestingly the cell metabolic activity was far higher 
for astrocytes that are incubated with the oxyGG hydrogels than of those without (hypoxic 
conditions - figure 3a/ supporting information figure S3, and normoxic conditions - 
supporting information figure S4). Since this strong effect was present even after one day, 
an increase in proliferation was unlikely. Indeed, the total DNA content of the wells was not 
increased, but instead was slightly decreased for the oxyGG treatment group for all time 
points except day 6 (figure 3b). Microscopy analysis generally showed little or no changes in 
cell morphology between the groups except that a few patches of cells containing extended 
processes could be observed in the oxyGG group (figure 3c).  
 
Having established that the oxyGG hydrogels appear nontoxic to astrocytes, the dual delivery 
study with C6 was carried out in both hypoxic conditions (figure 3d-f/ supporting 
information figure S5) and normoxic conditions (supporting information figure S6). The 
toxicity of various oxyGG formulations was carried out in comparison to untreated C6 cells 
and doxorubicin treated cells (“Free Dox” group – a concentration of 4 µg/mL was used 
which has previously been shown to be quite toxic to a variety of cancer cells in culture25). 
Formulations were also made without catalase (oxyGG – cat) with doxorubicin (+ dox) and 
without doxorubicin (– dox). Similarly to the astrocyte experiment oxyGG (henceforward 
termed oxyGG + cat) caused a significant rise in metabolic activity (figure 3d), reduced total 
DNA content (figure 3e) but did not affect cell morphology (figure 3f). Doxorubicin added to 
the media reduced the cellular metabolic activity to 33% after 1 day in culture. A far larger 
decrease could be obtained by both formulations of oxyGG without catalase indicating that 
they are releasing the reaction intermediate hydrogen peroxide to the cells. By the second and 
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third day, the differences in metabolic activity between the free doxorubicin and the oxyGG – 
cat formulations were smaller. No difference in total DNA content (figure 3e) was observed 
between doxorubicin and the dual delivery groups.  
 
 
 
 
Figure 3. In vitro analysis of the cytotoxicity of various formulations of calcium peroxide 
crosslinked gellan gum (oxyGG). Astrocyte cell metabolic activity (a) is increased by the 
addition of oxyGG, whilst the total DNA content is reduced until day 6 (b). Light microscope 
images of each time point are shown in the supporting information figure S3 with part (c) 
above showing untreated astrocytes (top) and oxyGG treated cells (bottom). The same trend 
is shown for C6 glioma (d + e) and the addition of free doxorubicin vastly reduces the 
cellular viability. Hydrogels formed without catalase (oxyGG – cat) show a further reduction 
in cell metabolic activity at all time points due to hydrogen peroxide release (supporting 
information figure S10). Light microscope images (f) show C6 glioma exposed to various 
treatment groups. All scale bars represent 100 µm, n=4 for all experiments, error bars 
represent +/- standard deviation. Asterisks (*) represent a statistically significant difference 
between cells alone and oxyGG hydrogels (unpaired student t test), whilst daggers (†) 
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represents statistically significant differences between free doxorubicin and the other toxic 
treatment groups (one way ANOVA, with Tukey’s multiple comparisons test).  
 
We had hypothesized that the additional oxygen generated by the oxyGG could enhance the 
toxicity of the doxorubicin. However, the cytotoxic effect of oxyGG + cat + dox group was 
either not different to that of the free doxorubicin group (day 1 and day 3) or even slightly less 
toxic (day 2). We have instead shown that oxyGG hydrogels without catalase are highly 
effective at killing C6 glioma cells in vitro due to the lack of conversion of hydrogen peroxide 
to oxygen. An additive effect of the dual delivery of both peroxide and doxorubicin was 
unfortunately impossible to observe since the oxyGG – cat hydrogels completely killed all the 
cells even after one day in culture.  
 
Due to the highly undesirable side effects of chemotherapy, there is currently much research 
into better delivery of chemotherapeutic agents. Biomaterial delivery systems such as 
nanotubes,26-27 nanoparticles,28-29 micelles,30 and drug eluting devices31 are being developed to 
reduce the dose required with the aim of reducing side effects and thus improving 
effectiveness. Herein, our approach has been to develop a material that delivers a defined 
quantity of drug along with oxygen or peroxide in an attempt to improve the efficiency of 
chemotherapeutic drug action. Whilst macroscale implants have been used for controlled drug 
release following brain tumor resection32, downscaling this gellan gum hydrogel for injection 
would be highly desirable, though the oxygen and drug release profiles would likely differ 
from the bulk material described herein. Whilst the killing effect of doxorubicin was not 
enhanced via the addition of oxygen to 2D in vitro culture of C6 glioma, it would be 
interesting to investigate whether additive effects are observed in 3D cancer spheroid models. 
Spheroid culture within hydrogel matrixes show higher resistance to doxorubicin treatment, 
even at doses of 4 µg/mL,25 and spheroid cultures have been shown to have hypoxic cores, 
which are effected by surrounding oxygen levels.33-34 Furthermore, such materials hold the 
potential to affect the efficiency of more oxygen dependent anti-cancer therapy strategies such 
as radiotherapy and photo-dynamic therapy, both of which require oxygen as a means of 
action.35-36 Since both radiotherapy and photo-dynamic therapy have been reported to be less 
effective in oxygen partial pressures of 25-30 mmHg (≈ 1.381 mg/L - 1.657 mg/L O2) and 15-
35 mmHg (≈ 0.892 mg/L - 1.933 mg/L O2) respectively, 37 oxygen producing materials may 
be able to increase the local oxygen concentration for more effective therapy. 
 
In conclusion we have developed an oxygen producing hydrogel based on the FDA approved 
natural polysaccharide gellan gum. This hydrogel encapsulates the solid peroxide calcium 
peroxide, catalase and doxorubicin if required. The oxygen release profile from the hydrogel 
disks showed elevated oxygen levels for up to 48 hours in normoxic conditions and 64 hours 
in hypoxic conditions, which was highly dependent on the amount of calcium peroxide 
embedded. The hydrogels were non-toxic towards C6 rat glioma cells and primary rat 
astrocytes if cultured in either normoxic or hypoxic conditions. The hydrogels could deliver a 
well-defined amount of doxorubicin to the C6 cells but the cytotoxic effect was not enhanced 
by the simultaneous release of oxygen. By omission of catalase during the gelation step, the 
gellan gum hydrogels become highly toxic due to the lack of conversion of the produced 
peroxide to oxygen. This work shows the first use of calcium peroxide as a crosslinking agent 
for gellan gum. By adjusting a variety of parameters such as the calcium peroxide to catalase 
ratio one could envisage tunable peroxide/oxygen release. Future plans aim to assess the use 
of these materials in three dimensional in vitro models for applications in photodynamic 
therapy where high oxygen/peroxide production may greatly enhance the therapeutic effect.   
 
Supporting Information 
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Supporting Information contains experimental method details and additional data. 
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Oxygen producing gellan gum hydrogels for dual delivery of either oxygen or peroxide 
with doxorubicin 
 
Ben Newland*, Marcel Baeger, Dimitri Eigel, Heike Newland, and Carsten Werner 
 
 
Experimental Section 
 
Materials: 
Gellan gum (Gelrite®) (henceforth termed GG) and all other reagents were purchased from 
Sigma Aldrich unless otherwise stated. Doxorubicin was purchased from LC Laboratories, 
USA. Water used throughout this water was deionized and filtered via the MilliQ ultrapure 
purifier system.  
 
Preparation of the gellan gum hydrogels: 
First 200 mg GG was dissolved in 20 mL water under constant stirring for 30 minutes in order 
to gain a solid content of 1% (w/v). Next, different amounts of CaCl2/CaO2 (Table S1) were 
added to the solution to adjust for different cross linking degrees. In order to buffer the basic 
gels to physiological pH (7.4), 0.1 M HEPES was added before the addition of CaO2 and 
different amounts of HCl (37%) as a 1.2 molar excess (obtained empirically) was added 
afterwards and the pH was checked before any further usage. Beginning with the lowest 
concentration, 2 mL of solution was taken and 100 µL gels were formed in plastic molds 
(cylindrical, ø8 mm). The gels formed when they were allowed to cool down to room 
temperature.  
 
 
 
 
Table S1: Production of the different cross linking degrees 
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Desired solid content 
of CaCl2/CaO2 
Initial solution  Mass of 
CaO2 added 
Vol. removed for 
gel formation 
Added volume of 
HCl (37%) 
0.1% (w/v) 20 mL 1%GG  
 
20 mg 2 mL 30 µL 
0.5% (w/v) 18 mL 1%GG 
0.1% CaCl2/CaO2 
72 mg 2 mL 108 µL 
1% (w/v) 16 mL 1%GG  
0.5% CaCl2/CaO2 
80 mg 2 mL 119 µL 
2% (w/v) 14 mL 1%GG  
1% CaCl2/CaO2 
140 mg 2 mL 209 µL 
 
To produce catalase containing gels, a 5 µL drop of catalase at 2 mg/mL was pipetted into the 
plastic mold before adding the other gellan gum hydrogel components. OxyGG – cat 
hydrogels received 5 µL of water instead (carrier solution for catalase). 1 µL of a 0.5 mg/mL 
doxorubicin stock solution (in water with 0.1% DMSO) was added to the plastic mold before 
addition of the gellan gum to create the oxyGG + dox groups. Experiments with the “free 
doxorubicin” groups received 1µL of the same doxorubicin stock solution directly into the 
cell culture medium.    
 
Rheological Analysis: 
8mm diameter disks of hydrogel were punched from the mold, and placed in PBS prior to 
rheological measurement. The storage modulus (G’) was measured by performing oscillatory 
shear experiments on an ARES LN2 rotational rheometer (TA Instruments, Eschborn, 
Germany). The distance between the oscillatory plates was reduced to 90% of the original gel 
height and then frequency sweeps were performed from 1 to 100 rad/s, at 25 °C with a strain 
amplitude of 2 %. A minimum of six independent experiments were performed and an 
average was calculated.   
Scanning Electron Microscopy (SEM) Analysis: 
The formed GG hydrogels were removed from the molds directly onto specimen stubs, dried 
in a vacuum oven at 37oC and sputter-coated with gold for 60 seconds (BALZERS SCD 050 
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Sputter Coater) before imaging. SEM studies were performed using a XL30 ESEM-FEG 
microscope (Philips) in high vacuum mode using accelerating voltages of 5 kV.  
 
Analysis of the Effect of the GG Hydrogels on pH: 
Gels of 0.1%, 0.5% and 1% CaO2 were made up as described and added to 1 ml of PBS in a 
24 well plate. The pH of the PBS was measured over three days using a VARIO® Cond pH 
meter. The equivalent mass of CaO2 which corresponds to a 1% CaO2 hydrogel was used as a 
positive control. 
 
Measurement of Oxygen Release: 
In order to measure the oxygen production of the CaO2 cross-linked gels, the oxygen sensor 
(Presens Oxy-4) was firstly calibrated. The 0% point was set by measuring the O2 level of a 
1% (w/v) sodium sulfite aqueous solution and the 100% point was set by measuring water 
which was oxygenated before by bubbling through air for 30 minutes. The medium in which 
the gels were analyzed was 700 µL PBS which was added to the measuring vial (fitted with a 
Presens spot sensor) one hour before addition of the gel to allow equilibrium to be reached. 
The oxyGG hydrogels were added directly into the measuring vial and analyzed by taking 
measurements every 5 minutes for 72 hours. Studies in severe hypoxia were performed via the 
same set up as described above, but carried out within a hypoxia chamber (Biospherix) set to 
0.1% oxygen held at 37 oC.  
 
Analysis of Doxorubicin Release: 
Doxorubicin release from the oxyGG hydrogels (0.5% CaO2) was performed by incubating 
the samples in 1 mL of PBS at 37°C. Cumulative drug release was measured using the 
doxorubicin-associated UV absorbance at 490 nm (Beckman Coulter, DU800, USA) at 
intervals of 15 minutes. oxyGG hydrogels without doxorubicin were used to establish an 
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absorbance reference value which was subtracted from all readings. Three experiments were 
performed and the average value for each concentration of loaded doxorubicin was plotted. 
 
Cell Culture and Cell Viability Analysis: 
Primary cortical astrocytes were extracted from newborn rat brains as previously described1, 
and C6 glioma cells (rat) were purchased from Sigma Aldrich. DMEM + GlutaMax (Gibco) 
was used for the culture of C6 cells and DMEM/F12 (Gibco) for the astrocyte cells. Both 
types of media were supplemented with 10% fetal bovine serum (FBS), 0.5% Streptomycin 
and 0.5% Penicillin. The cells were cultured in T75 culture flasks for 3 / 7 days 
(C6/Astrocytes resepectively) in a CO2 incubator (CO2 level: 5%; O2 level: 21%; 37°C) until 
usage for the experiments. 24-well plates were seeded with 10,000 cells per well (C6 glioma) 
or 20,000 cells per well (astrocytes) and were incubated for 24 hours in normoxic or hypoxic 
conditions (Biospherix hypoxia chamber set to 0.1% oxygen) to adhere.  
To analyze the toxicity of the gellan gum hydrogels with varying compositions (i.e. with 
catalase (+ cat), without catalase (- cat), with doxorubicin (+ dox) or without doxorubicin (- 
dox) the 8mm hydrogel disks were placed into the pre-seeded wells. After 24 hours of 
incubation in either normoxic (21% oxygen) or hypoxic (0.1% oxygen), light microscopy 
images were taken (Olympus), then the hydrogels and the media were removed and replaced 
with a 10% PrestoBlue solution in media. After 1 hour incubation 100 µl was transferred to a 
96 well plate for measurement in TECAN plate reader by fluorescence analysis (excitation wl: 
540 nm; emission wl: 590 nm; gain: 70; 3 flashes; lag time: 0µs; integration time: 20µs; room 
temperature). Four replicates were performed and the measurement for blank PrestoBlue (see 
supporting information Figure S7 for variance) was subtracted and the results were 
analyzed with MS Excel and the cell viability was plotted as a percentage of the control group 
of cells receiving no hydrogel. Separate well plates were seeded for each time point of the 
experiment and analyzed as described for the 24 hour incubation. 
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Analysis of Hydrogen Peroxide Production: 
Gellan gum hydrogels of 0.5 % were made up as described above (without and with 5 µL of  
2 mg/mL of catalase) and directly added to 1 mL of PBS in a 24 well plate (n = 4). 
Additionally, four gellan gum hydrogels without catalase were placed in wells, which already 
contained 5µL of catalase (2 mg/mL) in 1 mL of PBS. All gels were then incubated at room 
temperature away from light for 2 hours. Afterwards, 800 µL of the supernatant was removed 
from each GG hydrogel sample and transferred into a new 24 well plate. In order to measure 
the hydrogen peroxide release from the GG hydrogels, a fluorimetric hydrogen peroxide assay 
kit (Sigma Aldrich (MAK 166)). 50 µL of the standard was added to a 96 well plate in 
duplicate. To the same 96 well plate, 50 µL of the removed supernatant was added in 
quadruplicate. The supernatant was diluted if necessary in a ratio of 1:1000 with PBS. 
Subsequently, a so-called Master Mix was prepared, which contained 50 µL of infra-red 
peroxidase, 200 µL (20 units/mL) of horseradish peroxidase and 4.75 mL of assay buffer. 50 
µL of this Master Mix was added to each of the wells (standard, sample and blank) and mixed 
well, whereby the total volume amount in a well was 100 µL. After 20 minutes of incubation 
at room temperature protected from light, the fluorescence intensity was measured using the 
fluorescence plate reader TECAN GENios (excitation wl: 640 nm; emission wl: 680 nm; gain: 
112; 3 flashes; lag time: 0µs; integration time: 20µs; room temperature). The blank for the 
assay was the value obtained for the 0 µM hydrogen peroxide standard. This value was 
subtracted from all readings. The final hydrogen peroxide release concentration of the GG 
samples was determined from the hydrogen peroxide standard curve. 
 
 
Statistical Analysis: 
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This was performed using GraphPad Prism 5 software, using a student’s t test or one way 
analysis of variance (ANOVA). A statistical significant difference between the groups in a 
time point is represented by asterisks (*) or daggers (†) on the graph, corresponding to the 
following P values: * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, ****P≤ 0.0001. Error bars 
represent ± standard deviation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Data: 
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Figure S1 – Rheological analysis of the hydrogels of different compositions after incubation 
in PBS at 37oC for 24 hours either without being buffered and neutralized (i.e. just CaO2 
added)(a) or buffered (HEPES and HCl added)(b)showing that the buffering process reduces 
the stiffness of the hydrogels (2% CaO2 gels were not analyzed as they were two fragile to 
handle properly). Corresponding scanning electron microscope images (c) of the hydrogel 
surfaces showing the effect of increasing CaO2 on surface morphology.  
 
 
 
Figure S2 – Analysis of the pH of PBS containing various compositions of oxyGG hydrogels 
in comparison to calcium peroxide (control), showing that despite the production of oxygen 
for ~44 hours (Figure 2a), no change in pH can be observed over this period or beyond.  
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Figure S3 – Representative images of the astrocytes in hypoxic conditions (0.1% oxygen) at 
each time point with (right hand side) or without (left) oxyGG (scale bars = 100 µm).  
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Figure S4 – The metabolic activity of astrocytes cultured with or without oxyGG in normoxic 
conditions as measured by the PrestoBlue assay (n=4 error bars represent +/- standard 
deviation). Representative images of the astrocytes in normoxic conditions with or without 
oxyGG (scale bars =100 µm).  
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Figure S5 – Representative light microscopy images of C6 glioma cells cultured in hypoxic 
conditions (0.1% oxygen) with a variety of oxyGG formulations or free doxorubicin in the 
medium (free dox). (Scale bars = 100 µm)  
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Figure S6 – C6 glioma cell metabolic activity in normoxic conditions after incubation for 1,3 
or 6 days with a variety of oxyGG formulations or free doxorubicin in the medium (free dox).  
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Figure S7 – Analysis of the blank measurements for the PrestoBlue assay for each condition. 
Neither the catalase, doxorubicin nor the oxyGG effect the blank presto blue reading, whether 
the they were first removed from the well (grey bars) or even left in the wells during the 1 
hour PrestoBlue incubation. This shows that they do not interact with the assay to give a false 
positive/negative.  
 
 
 
Figure S8 – Oxygen release profile of oxyGG with catalase (a) and without the addition of 
catalase into the hydrogel (b) in normoxic conditions. 
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Figure S9 – Oxygen release profile of oxyGG with catalase (a) and without the addition of 
catalase into the hydrogel (b) under hypoxic conditions. 
 
 
Figure S10 – oxyGG hydrogels formed without catalase cause hydrogen peroxide release 
whether they are buffered/neutralized (oxyGG – cat) or not buffered/neutralized (-buffer – 
cat). The addition of catalase reduces the hydrogen peroxide to baseline levels (n=4, error 
bars represent +/- standard deviation). 
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Figure S11 – analysis of the addition of the equivalent amount of hydrogen peroxide to the 
oxygen sensing cuvette to that theoretically produced by oxyGG (0.5%). Catalase was also 
added to the media (10 units) to match that contained within oxyGG (0.5%) hydrogels. There 
is a sudden burst release which drops off quickly as all the H2O2 is converted to oxygen and 
water.  
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